文献速递肿瘤 PET/CT放射性药物与辐射防护

炎症PET显像的新靶点:非FDG示踪剂临床研究综述

New targets for PET imaging of inflammation.
PubMed 文献 · Semin Nucl Med · 2026-04-20

本文综述了非[18F]FDG PET示踪剂在人类炎症性疾病中的临床研究现状,涵盖FAP抑制剂、生长抑素类似物、TSPO、趋化因子受体4、叶酸受体、免疫PET及细菌特异性示踪剂等。现有证据提示这些示踪剂可提供成纤维细胞活化、免疫细胞募集、神经炎症、巨噬细胞活性或病原体特异性过程的信息,其中FAP抑制剂PET和生长抑素受体靶向PET较有前景,但数据多为初步且异质。

要点

  • [18F]FDG仍是最广泛使用的炎症PET示踪剂,但特异性有限且受高血糖和皮质激素影响。
  • 非FDG示踪剂靶向成纤维细胞活化、免疫细胞、神经炎症、巨噬细胞及病原体等不同通路。
  • FAP抑制剂PET和生长抑素受体靶向PET较有前景,但证据多为初步,需更大前瞻性研究。

核心结论

  • 新兴PET示踪剂有望改进炎症性疾病的非侵入性评估,但更广泛的临床整合前需更大规模前瞻性研究和成像方案标准化。

研究设计与样本

  • 本文为综述,汇总了在人类炎症性疾病中研究的最相关非[18F]FDG PET示踪剂的当前临床图景。

主要发现

  • [18F]FDG广泛用于不明原因发热或炎症、大血管炎、结节病、炎症性肠病、腹膜后纤维化和IgG4相关性疾病等。
  • 非FDG示踪剂可提供成纤维细胞活化、免疫细胞募集、神经炎症、巨噬细胞活性或病原体特异性过程的信息,改善特定情境下的病灶表征。
  • FAP抑制剂PET和生长抑素受体靶向PET显得尤其有前景,但数据仍异质且多为初步。

关键数值与推荐

  • 综述涉及的非FDG示踪剂包括FAP抑制剂放射性配体、放射性标记生长抑素类似物、TSPO示踪剂、趋化因子受体4靶向药物、叶酸受体配体、免疫PET方法和细菌特异性示踪剂。

临床怎么用

  • 在特定临床情境下,可考虑使用非FDG PET示踪剂补充[18F]FDG提供的信息,以改善炎症病灶表征。
  • FAP抑制剂PET和生长抑素受体靶向PET是目前较有前景的选择,但应认识到证据多为初步。

局限性

  • 非FDG示踪剂的数据仍异质且大多为初步研究。
  • 更广泛的临床整合前需要更大规模前瞻性研究和成像方案标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Positron emission tomography (PET) plays an established role in the evaluation of infectious and inflammatory disorders, with [18F]fluorodeoxyglucose ([18F]FDG) remaining the most widely used tracer in clinical practice. Its broad availability, high sensitivity, and whole-body capability have supported its use in conditions such as fever or inflammation of unknown origin, large-vessel vasculitis, sarcoidosis, inflammatory bowel disease, retroperitoneal fibrosis, and immunoglobulin G4-related disease. However, [18F]FDG has important limitations, including reduced specificity, limited performance in sites of high physiologic uptake, and susceptibility to confounding factors such as hyperglycemia and corticosteroid therapy. These shortcomings have stimulated growing interest in alternative PET radiopharmaceuticals targeting distinct inflammatory pathways. This review summarizes the current clinical landscape of most relevant non-[18F]FDG PET tracers investigated in human inflammatory disorders, including fibroblast activation protein inhibitor radioligands, radiolabeled somatostatin analogues, translocator protein tracers, chemokine receptor 4-directed agents, folate receptor ligands, immuno-PET approaches, and bacteria-specific tracers. Available evidence suggests that these agents may provide complementary information on fibroblast activation, immune-cell recruitment, neuroinflammation, macrophage activity, or pathogen-specific processes, thereby improving lesion characterization in selected settings. Among them, fibroblast activation protein inhibitor PET and somatostatin receptor-targeted PET appear particularly promising, although data remain heterogeneous and mostly preliminary. Overall, emerging PET tracers have the potential to refine the noninvasive assessment of inflammatory disease, but larger prospective studies and standardization of imaging protocols are needed before broader clinical integration.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Treglia G, Rizzo A, Albano D, et al. New targets for PET imaging of inflammation. Semin Nucl Med. 2026. PMID: 42014234. doi:10.1053/j.semnuclmed.2026.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。